Robinette Huston, MD
Family Medicine · Dublin, OHNPI 1356425995
Payments from drug & device makers
Across 279 payments — averaging $26.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$705
- GSK$642
- Amarin Pharma, Inc.$446
- Amgen$425
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,488100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 89 | $1,431 |
| AstraZeneca | 28 | $1,194 |
| Novo Nordisk | 32 | $705 |
| GSK | 22 | $642 |
| Amarin Pharma, Inc. | 9 | $446 |
| Amgen | 7 | $425 |
| Kowa Pharmaceuticals America, Inc. | 5 | $365 |
| Teva Pharmaceuticals USA, Inc. | 12 | $317 |
| Lilly USA, LLC | 14 | $240 |
| Biohaven Pharmaceuticals, Inc. | 2 | $213 |
| Johnson & Johnson | 11 | $202 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $199 |
| Merck | 7 | $192 |
| Boehringer Ingelheim | 4 | $138 |
| Idorsia Pharmaceuticals US Inc | 2 | $128 |
| Mannkind Corporation | 1 | $126 |
| Genentech USA, Inc. | 1 | $95 |
| Jazz Pharmaceuticals Inc. | 1 | $85 |
| Pfizer | 5 | $75 |
| Abbott | 3 | $57 |
| IBSA Pharma Inc. | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Exact Sciences | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Gilead | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Vertiflex, Inc. | 1 | $12 |
| Medicure Pharma Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,509 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $112,511 |
| EliquisApixaban | 83 | $77,084 |
| MounjaroTirzepatide | 42 | $44,585 |
| JardianceEmpagliflozin | 25 | $34,794 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $31,453 |
| FarxigaDapagliflozin Propanediol | 16 | $25,084 |
| TrulicityDulaglutide | 16 | $23,826 |
| Bydureon BciseExenatide Microspheres | 16 | $23,223 |
| ProliaDenosumab | 11 | $18,461 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $12,468 |
| XareltoRivaroxaban | 15 | $11,209 |
| Duloxetine Hcl | 144 | $7,311 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 21 | $4,603 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,767 |
| Atorvastatin Calcium | 448 | $3,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $705 | $112,51173 claims |
| PfizerEliquis | $75 | $77,08483 claims |
| Lilly USA, LLCMounjaro, Trulicity | $240 | $68,41158 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $642 | $48,52463 claims |
| Boehringer IngelheimJardiance | $138 | $34,79425 claims |
| AstraZenecaFarxiga | $1,194 | $25,08416 claims |
| AmgenProlia | $425 | $18,46111 claims |
| Johnson & JohnsonXarelto | $202 | $11,20915 claims |
| AbbVieSynthroid | $1,431 | $1,29543 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Dublin
- Henry YougaDublin$640K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.